{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:28:41Z","timestamp":1794090521285,"version":"4.8.0"},"reference-count":14,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,25]]},"DOI":"10.31744\/einstein_journal\/2022ao6500","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T12:32:09Z","timestamp":1650976329000},"source":"Crossref","is-referenced-by-count":8,"title":["C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and\/or mesalazine: a real-life study"],"prefix":"10.31744","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8546-4071","authenticated-orcid":false,"given":"Rejani Cristine Faustino dos","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-2182","authenticated-orcid":false,"given":"Wilson Roberto","family":"Catapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-2499","authenticated-orcid":false,"given":"Andr\u00e9 Akira Ramos","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2775-8068","authenticated-orcid":false,"given":"Jaques","family":"Waisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"3","key":"key20220426083157_B1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","unstructured":"1. Peyrin-Biroulet L, Pan\u00e9s J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14(3):348-54.e17. Review.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"key20220426083157_B2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders","volume":"11","author":"Magro","year":"2017","unstructured":"2. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zag\u00f3rowicz E, Raine T, Harbord M, Rieder F; European Crohn\u2019s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649-70.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"key20220426083157_B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"Gomoll\u00f3n","year":"2017","unstructured":"3. Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"key20220426083157_B4","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-013-0315-7","article-title":"Deep remission in inflammatory bowel disease: looking beyond symptoms","volume":"15","author":"Zallot","year":"2013","unstructured":"4. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15(3):315. Review.","journal-title":"Curr Gastroenterol Rep"},{"issue":"10114","key":"key20220426083157_B5","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicenter, randomized, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2018","unstructured":"5. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Va\u0148\u00e1sek T, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicenter, randomized, controlled phase 3 trial. Lancet. 2018;23;390(10114):2779-89.","journal-title":"Lancet"},{"issue":"5","key":"key20220426083157_B6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/gut.49.5.656","article-title":"Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide","volume":"49","author":"Lowry","year":"2001","unstructured":"6. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide. Gut. 2001;49(5):656-64.","journal-title":"Gut"},{"issue":"4","key":"key20220426083157_B7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ibd.21083","article-title":"Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis","volume":"16","author":"Chebli","year":"2010","unstructured":"7. Chebli LA, Chaves LD, Pimentel FF, Guerra DM, Barros RM, Gaburri PD, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2010;16(4):613-9.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"key20220426083157_B8","first-page":"PI19","article-title":"Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study","volume":"15","author":"Pinto","year":"2009","unstructured":"8. Pinto AL, Chebli LA, Ribeiro MS, Pace FH, Moraes JP, do Amaral FJ Jr, et al. Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. Med Sci Monit. 2009; 15(5):PI19-26.","journal-title":"Med Sci Monit"},{"key":"key20220426083157_B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4067\/S0034-98872015000100001","article-title":"Eventos adversos en la terapia farmacol\u00f3gica de la enfermedad inflamatoria intestinal","volume":"143","author":"Meyer","year":"2015","unstructured":"9. Meyer L, Simian D, Lubascher J, Acu\u00f1a R, Figueroa C, Silva G, et al. Eventos adversos en la terapia farmacol\u00f3gica de la enfermedad inflamatoria intestinal. Rev Med Chile. 2015;143:7-13.","journal-title":"Rev Med Chile"},{"issue":"5","key":"key20220426083157_B10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1590\/S0104-42302008000500014","article-title":"Toxicidade da azatioprina na doen\u00e7a de Crohn: incid\u00eancia, abordagem e evolu\u00e7\u00e3o","volume":"54","author":"Colli","year":"2008","unstructured":"10. Colli MV, Amaro AT, Pinto AL, Gaburri PD, Chebli JM. Toxicidade da azatioprina na doen\u00e7a de Crohn: incid\u00eancia, abordagem e evolu\u00e7\u00e3o. Rev Assoc Med Bras. 2008;54(5):415-21.","journal-title":"Rev Assoc Med Bras"},{"issue":"7","key":"key20220426083157_B11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine","volume":"128","author":"L\u00e9mann","year":"2005","unstructured":"11. L\u00e9mann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y; Groupe D\u2019Etude Th\u00e9rapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128(7):1812-8.","journal-title":"Gastroenterology"},{"issue":"5","key":"key20220426083157_B12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.crohns.2011.11.007","article-title":"Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up","volume":"6","author":"Constantino","year":"2012","unstructured":"12. Constantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W. Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6(5):588-96.","journal-title":"J Crohns Colitis"},{"issue":"15","key":"key20220426083157_B13","doi-asserted-by":"crossref","first-page":"e3326","DOI":"10.1097\/MD.0000000000003326","article-title":"Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease: an observational study","volume":"95","author":"Fangbin","year":"2016","unstructured":"13. Fangbin Z, Xiang G, Liang D, Hui L, Xueding W, Baili C, et al. Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease: an observational study. Medicine (Baltimore). 2016;95(15):e3326.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"key20220426083157_B14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ajg.2009.685","article-title":"Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review","volume":"105","author":"Jackson","year":"2010","unstructured":"14. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105(3):525-39. Review.","journal-title":"Am J Gastroenterol"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T12:32:22Z","timestamp":1650976342000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/c-reactive-protein-levels-and-prevalence-of-leukopenia-in-patients-with-inflammatory-bowel-disease-treated-with-azathioprine-and-or-mesalazine-a-real-life-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":14,"alternative-id":["10.31744\/einstein_journal\/2022AO6500"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2022ao6500","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"eAO6500"}}